Dr. Reddy’s has launched Toripalimab, a novel immuno-oncology drug, in India for treating recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab, already approved by USFDA and EMA, will be marketed as Zytorvi. It shows significant efficacy in combination with chemotherapy drugs gemcitabine and cisplatin, and also as monotherapy for patients with disease progression. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
